BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance Unchanged
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BioMarin Announces Second Quarter 2015 Financial Results and Company Update
August 3, 2015 4:02 PM EDT- In First Six Months of 2015 Vimizim Sales Top $104 million and Total BioMarin Revenue Grows 32% Y/Y - First Patients Enrolled in 4th Cohort of Phase 2 Study of Vosoritide for the Treatment of Achondroplasia
Financial Highlights ($ in millions, except per share data, unaudited)
 Three Months Ended June 30, Six Months Ended June 30,  2015 2014 % Change 2015 2014 % Change        Total BioMarin Revenue  $ 250.5  $ 191.8 31%  $ 453.8  $ 343.3 32% Vimizim Net Product Revenue  53.9  14.3 n.m.  104.5... More